Responses of primary pulmonary aspergillosis in persistently neutropenic rabbits to antifungal therapy as measured by the following panel of outcome parameters: lung weight, pulmonary infarct score, mean concentration of residual organisms (log CFU per gram) in pulmonary tissue (n = 8; 95% confidence interval in UC, 1.07 to 2.41) (GenericAmB0.5 [n = 9] 95% confidence interval, 0.28 to 1.69; GenericAmB1 [n = 9] 95% confidence interval, −0.08 to 1.10; Fungizone0.5 [n = 9] 95% confidence interval, 0.62 to 1.94; Fungizone1 [n = 9] 95% confidence interval, −0.14 to 0.83), and survival. Lung weight and pulmonary infarct scores are expressed as the mean ± the standard error of the mean. In comparison with UC, P values are indicated as follows: *, P < 0.05; †, P < 0.01; ¶, P < 0.001. For the survival measurements, the values on the y axis are probability of survival, P ≤ 0.001 (log rank test) for all treatment groups in comparison with UC.

Expression of galactomannan antigenemia in persistently neutropenic rabbits with pulmonary aspergillosis treated with GenericAmB0.5, GenericAmB1, Fungizone0.5, or Fungizone1. Galactomannan antigenemia levels were significantly lower on day 8 in all treatment groups in comparison with that of UC (¶, P ≤ 0.01). All values represent means ± the standard errors of the means.